

TABLES ACCOMPANYING COMMENT ON KEEGAN ET AL.

Tables A to D below support a journalreview.com comment on Keegan, THM, Clarke CA, Chang ET, et al. Disparities in survival after Hodgkins lymphoma: a population based study. *Cancer Causes Control* 2009;20:1881-1892. The comment may be found at:

Table A is based on Table 5 of the Keegan article. In the columns, “Y5S” means the 5-year survival rate for the younger (15-44) group¹ and “Y5M” means the 5-year mortality rate for that group. With the knowledge that “O” stands for the older (45 and above) and the numbers 10 and 15 represent 10-year and 15-year survival/mortality, a reader should understand the meanings of all the column headings. L stands for low SES (lowest three income quintiles) and H stands for higher SES (highest two income quintiles).

¹ Technically the rate is the “relative survival rate,” by which is meant the ratio of the survival rate of the group with the condition to the survival rate of the same group in the overall population without the condition. I do not use the term in the text above in order not to confuse the concept with concept of relative survival (or mortality) of low versus high SES persons with the condition (which actually involves the relative difference between the relative survival rates).

**Table A Mortality and Survival Rates of Persons with Hodgkins Lymphoma, by Various Demographic Groupings
(from Table 5 of Keegan et al.)**

Group	SES	Y5S	Y5M	O5S	O5M	Y10S	Y10M	O10S	O10M	Y15S	Y15M	O15S	O15M
White	L	90.00%	10.00%	61.60%	38.40%	86.10%	13.90%	53.20%	46.80%	82.10%	17.90%	44.80%	55.20%
White	H	93.50%	6.50%	69.80%	30.20%	90.70%	9.30%	59.80%	40.20%	88.10%	11.90%	53.50%	46.50%
Black	L	84.10%	15.90%	68.70%	31.30%	78.80%	21.20%	56.10%	43.90%	74.60%	25.40%	50.80%	49.20%
Black	H	85.40%	14.60%	78.50%	21.50%	80.40%	19.60%	75.20%	24.80%	80.40%	19.60%	72.00%	28.00%
Hispanic	L	88.90%	11.10%	56.00%	44.00%	82.20%	17.80%	48.50%	51.50%	78.10%	21.90%	41.90%	58.10%
Hispanic	H	91.90%	8.10%	64.40%	35.60%	84.70%	15.30%	58.10%	41.90%	79.70%	20.30%	53.90%	46.10%
API	L	90.60%	9.40%	50.40%	49.60%	87.50%	12.50%	35.60%	64.40%	81.40%	18.60%	27.80%	72.20%
API	H	92.60%	7.40%	71.90%	28.10%	91.00%	9.00%	62.10%	37.90%	89.00%	11.00%	56.00%	44.00%
Male	L	86.90%	13.10%	60.10%	39.90%	82.10%	17.90%	51.60%	48.40%	77.60%	22.40%	43.70%	56.30%
Male	H	91.80%	8.20%	70.90%	29.10%	88.30%	11.70%	60.50%	39.50%	84.70%	15.30%	52.00%	48.00%
Female	L	91.70%	8.30%	60.00%	40.00%	87.10%	12.90%	50.50%	49.50%	83.30%	16.70%	43.80%	56.20%
Female	H	94.30%	5.70%	67.80%	32.20%	91.40%	8.60%	60.20%	39.80%	89.60%	10.40%	57.70%	42.30%
Stage I	L	93.70%	6.30%	78.10%	21.90%	91.50%	8.50%	65.50%	34.50%	86.40%	13.60%	54.10%	45.90%
Stage I	H	96.50%	3.50%	80.10%	19.90%	95.40%	4.60%	73.00%	27.00%	93.30%	6.70%	65.70%	34.30%
Stage II	L	91.80%	8.20%	70.20%	29.80%	87.30%	12.70%	59.30%	40.70%	84.10%	15.90%	51.80%	48.20%
Stage II	H	95.20%	4.80%	79.60%	20.40%	93.10%	6.90%	68.60%	31.40%	90.30%	9.70%	64.10%	35.90%
StageIII/V	L	83.90%	16.10%	46.70%	53.30%	78.60%	21.40%	39.30%	60.70%	73.90%	26.10%	33.30%	66.70%
StageIII/V	H	87.70%	12.30%	56.60%	43.40%	83.00%	17.00%	47.30%	52.70%	79.90%	20.10%	42.20%	57.80%

Table B show the ratios of the survival rates of the high SES group to the low SES group and the ratios of the mortality rates of the low SES group to the high SES group by each demographic (or Hodgkins lymphoma stage) grouping.

Table B Ratios (a) High SES to Low SES Survival Rates and (b) Low SES to High SES Mortality Rates, from Rates in Table A

Group	Y5SRatio	Y5MRatio	O5SRatio	O5MRatio	Y10SRatio	Y10MRatio	O10SRratio	O10MRatio	Y15SRatio	Y15MRatio	O15SRatio	O15MRatio
White	1.04	1.54	1.13	1.27	1.05	1.49	1.12	1.16	1.07	1.50	1.19	1.19
Black	1.02	1.09	1.14	1.46	1.02	1.08	1.34	1.77	1.08	1.30	1.42	1.76
Hispanic	1.03	1.37	1.15	1.24	1.03	1.16	1.20	1.23	1.02	1.08	1.29	1.26
API	1.02	1.27	1.43	1.77	1.04	1.39	1.74	1.70	1.09	1.69	2.01	1.64
Male	1.06	1.60	1.18	1.37	1.08	1.53	1.17	1.23	1.09	1.46	1.19	1.17
Female	1.03	1.46	1.13	1.24	1.05	1.50	1.19	1.24	1.08	1.61	1.32	1.33
Stage I	1.03	1.80	1.03	1.10	1.04	1.85	1.11	1.28	1.08	2.03	1.21	1.34
Stage II	1.04	1.71	1.13	1.46	1.07	1.84	1.16	1.30	1.07	1.64	1.24	1.34
Stagelll/V	1.05	1.31	1.21	1.23	1.06	1.26	1.20	1.15	1.08	1.30	1.27	1.15

Table C reorders the columns in order to facilitate the comparisons discussed in the text of the comment on Keegan et al.

Table C Ratios (a) High SES to Low SES Survival Rates and (b) Low SES to High SES Mortality Rates, from Rates in Table A (reordered from Table B)

Group	Y5SRatio	O5SRatio	Y5MRatio	O5MRatio	Y10SRatio	O10SRratio	Y10MRatio	O10MRatio	Y15SRatio	O15SRatio	Y15MRatio	O15MRatio
White	1.04	1.13	1.54	1.27	1.05	1.12	1.49	1.16	1.07	1.19	1.50	1.19
Black	1.02	1.14	1.09	1.46	1.02	1.34	1.08	1.77	1.08	1.42	1.30	1.76
Hispanic	1.03	1.15	1.37	1.24	1.03	1.20	1.16	1.23	1.02	1.29	1.08	1.26
API	1.02	1.43	1.27	1.77	1.04	1.74	1.39	1.70	1.09	2.01	1.69	1.64
Male	1.06	1.18	1.60	1.37	1.08	1.17	1.53	1.23	1.09	1.19	1.46	1.17
Female	1.03	1.13	1.46	1.24	1.05	1.19	1.50	1.24	1.08	1.32	1.61	1.33
Stage I	1.03	1.03	1.80	1.10	1.04	1.11	1.85	1.28	1.08	1.21	2.03	1.34
Stage II	1.04	1.13	1.71	1.46	1.07	1.16	1.84	1.30	1.07	1.24	1.64	1.34
Stagelll/V	1.05	1.21	1.31	1.23	1.06	1.20	1.26	1.15	1.08	1.27	1.30	1.15

Table D shows effects of low SES on cancer outcomes for each of the groupings in the above tables, according to age and temporal survival category, using the procedure discussed on the [Solutions](#) sub-page of [Measuring Health Disparities](#) page of [jpscanlan.com](#). In order to facilitate various comparisons, an excel file of this table is made available [here](#).

Table D Effects of Low SES on Hodgkins Lymphoma Outcomes by Category in Keegan Table 5

AgeSurvCat	Group	HighSESSurv	LowSESSurv	EES
5Y	White	93.50%	90.00%	0.25
5Y	Black	85.40%	84.10%	0.06
5Y	Hispanic	91.90%	88.90%	0.18
5Y	API	92.60%	90.60%	0.13
5Y	Male	91.80%	86.90%	0.28
5Y	Female	94.30%	91.70%	0.2
5Y	Stage I	96.50%	93.70%	0.29
5Y	Stage II	95.20%	91.80%	0.28
5Y	Stagelll/V	87.70%	83.90%	0.18
5O	White	69.80%	61.60%	0.24
5O	Black	78.50%	68.70%	0.3
5O	Hispanic	64.40%	56.00%	0.22
5O	API	71.90%	50.40%	0.57
5O	Male	70.90%	60.10%	0.3
5O	Female	67.80%	60.00%	0.22
5O	Stage I	80.10%	78.10%	0.07
5O	Stage II	79.60%	70.20%	0.3
5O	Stagelll/V	56.60%	46.70%	0.26
10Y	White	90.70%	86.10%	0.26
10Y	Black	80.40%	78.80%	0.06
10Y	Hispanic	84.70%	82.20%	0.12
10Y	API	91.00%	87.50%	0.2
10Y	Male	88.30%	82.10%	0.28
10Y	Female	91.40%	87.10%	0.23
10Y	Stage I	95.40%	91.50%	0.32

Table D Effects of Low SES on Hodgkins Lymphoma Outcomes by Category in Keegan Table 5

AgeSurvCat	Group	HighSESSurv	LowSESSurv	EES
10Y	Stage II	93.10%	87.30%	0.35
10Y	StageIII/V	83.00%	78.60%	0.17
10O	White	59.80%	53.20%	0.17
10O	Black	75.20%	56.10%	0.54
10O	Hispanic	58.10%	48.50%	0.26
10O	API	62.10%	35.60%	0.69
10O	Male	60.50%	51.60%	0.23
10O	Female	60.20%	50.50%	0.25
10O	Stage I	73.00%	65.50%	0.23
10O	Stage II	68.60%	59.30%	0.25
10O	StageIII/V	47.30%	39.30%	0.21
15Y	White	88.10%	82.10%	0.26
15Y	Black	80.40%	74.60%	0.2
15Y	Hispanic	79.70%	78.10%	0.06
15Y	API	89.00%	81.40%	0.35
15Y	Male	84.70%	77.60%	0.28
15Y	Female	89.60%	83.30%	0.29
15Y	Stage I	93.30%	86.40%	0.4
15Y	Stage II	90.30%	84.10%	0.3
15Y	StageIII/V	79.90%	73.90%	0.2
15O	White	53.50%	44.80%	0.24
15O	Black	72.00%	50.80%	0.57
15O	Hispanic	53.90%	41.90%	0.31
15O	API	56.00%	27.80%	0.76
15O	Male	52.00%	43.70%	0.23
15O	Female	57.70%	43.80%	0.37

Table D Effects of Low SES on Hodgkins Lymphoma Outcomes by Category in Keegan Table 5

AgeSurvCat	Group	HighSESSurv	LowSESSurv	EES
150	Stage I	65.70%	54.10%	0.31
150	Stage II	64.10%	51.80%	0.32
150	StageIII/V	42.20%	33.30%	0.25